



Longstaff, L., Porter, E. L., Crossley, V. J., Hayhow, S., Helps, C. R., & Tasker, S. (2017). Feline coronavirus quantitative reverse-transcriptase polymerase chain reaction on effusion samples in cats with and without feline infectious peritonitis. *Journal of Feline Medicine and Surgery*, 19(2), 240-245. DOI: 10.1177/1098612X15606957

Peer reviewed version

Link to published version (if available):

[10.1177/1098612X15606957](https://doi.org/10.1177/1098612X15606957)

[Link to publication record in Explore Bristol Research](#)

PDF-document

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/pure/about/ebr-terms.html>

1 **Feline coronavirus quantitative reverse-transcriptase polymerase chain reaction on**  
2 **effusion samples in cats with and without feline infectious peritonitis**

3  
4 **L. Longstaff\*, E. Porter\*, V. J. Crossley, S. E. Hayhow, C. R. Helps, & S. Tasker<sup>§</sup>**

5  
6 Longstaff, L. The Feline Centre, Langford Veterinary Services and School of Veterinary  
7 Sciences, University of Bristol, Langford, Bristol, UK.

8 Porter, E. School of Veterinary Sciences, University of Bristol, Langford, Bristol, UK.

9 Crossley, V. The Feline Centre, Langford Veterinary Services and School of Veterinary  
10 Sciences, University of Bristol, Langford, Bristol, UK.

11 Hayhow, S. School of Veterinary Sciences, University of Bristol, Langford, Bristol, UK.

12 Helps, C. R. Molecular Diagnostic Unit, Langford Veterinary Services, Langford, Bristol, BS40  
13 5DU.

14 \* These authors contributed equally to this manuscript

15  
16 **<sup>§</sup>Corresponding author**

17 Séverine Tasker BSc BVSc PhD DSAM DipECVIM-CA FHEA MRCVS

18 E-mail: [s.tasker@bristol.ac.uk](mailto:s.tasker@bristol.ac.uk)

19 Address: The Feline Centre and Molecular Diagnostic Unit, Langford Veterinary Services and  
20 School of Veterinary Sciences, University of Bristol, Langford, Bristol, UK.

21 Telephone: + 44 (0) 117 928 9280

22  
23 **Keywords:** feline, diagnosis, coronavirus, mutation, effusion, feline infectious peritonitis

- 24 **Abbreviated short title:** Feline coronavirus polymerase chain reaction in the diagnosis of wet  
25 feline infectious peritonitis

26 **Abstract**

27 **Objectives:** To determine whether feline coronavirus (FCoV) RNA in effusion samples can be  
28 used as a diagnostic marker of feline infectious peritonitis (FIP), and in FCoV RNA positive  
29 samples, to examine amino acid codons in the FCoV spike protein at positions 1058 and 1060  
30 where leucine and alanine, respectively, have been associated with systemic or virulent (FIP)  
31 FCoV infection.

32 **Methods:** Total RNA was extracted from effusion samples from 20 cats with confirmed FIP and  
33 23 cats with other diseases. Feline coronavirus RNA was detected using a reverse transcriptase  
34 quantitative polymerase chain reaction assay (qRT-PCR) and positive samples underwent  
35 pyrosequencing of position 1058 and Sanger sequencing of position 1060 in the FCoV spike  
36 protein.

37 **Results:** Seventeen (85%) of effusion samples from 20 cats with FIP were positive for FCoV  
38 RNA, whereas none of the 23 cats with other diseases were positive. Pyrosequencing of the 17  
39 FCoV positive samples showed that 11 (65%) of cats had leucine and 2 (12%) had methionine  
40 at position 1058. Of the two samples with methionine, one had alanine at position 1060.

41 **Conclusions and relevance:** A positive FCoV qRT-PCR result on effusions appears specific  
42 for FIP and may be a useful diagnostic marker for FIP in cats with effusions. The majority of  
43 FCoVs contained amino acid changes previously associated with systemic spread or virulence  
44 (FIP) of the virus.

45

46 **Introduction**

47 Feline coronavirus (FCoV) infection is common in domestic cat populations worldwide<sup>1-3</sup>. Most  
48 infections are enteric and self-limiting. In a small number of cases, FCoV infection can lead to  
49 the development of feline infectious peritonitis (FIP), a significant cause of mortality in young  
50 cats.

51 Definitive diagnosis of FIP relies on histopathological examination of affected tissues, ideally  
52 with detection of intracellular FCoV antigen by immunostaining<sup>1, 4, 5</sup>. Obtaining tissue samples is  
53 invasive and problematic for *ante mortem* diagnosis. In many FIP cases, abdominal, pleural  
54 and/or pericardial effusions develop<sup>2</sup>, which can usually be easily obtained for diagnostic  
55 testing. Previous studies have reported the use of FCoV antigen staining in effusion samples in  
56 the diagnosis of FIP, with sensitivity and specificity of 57-100% and 71.5-100%, respectively<sup>6-9</sup>.

57 Feline coronavirus RNA can be detected in samples using conventional or quantitative reverse  
58 transcriptase polymerase chain reaction assays (qRT-PCR). Studies on tissues using qRT-  
59 PCRs have found that cats with FIP have significantly higher FCoV loads in tissues than healthy  
60 or sick (non-FIP) FCoV infected cats<sup>5, 10, 11</sup>. It is possible that the same is true for effusion  
61 samples. Previous studies performing FCoV conventional PCR on effusion samples from cats  
62 with FIP have shown promising results, but were limited either by lack of definitive diagnosis of  
63 cases<sup>12</sup>, or lack of control non-FIP cats<sup>13</sup>.

64 The aim of this study was to perform FCoV qRT-PCR on effusions collected from cats with and  
65 without confirmed FIP to investigate whether the presence of FCoV RNA in effusions is helpful  
66 in diagnosing FIP. In addition, it has been reported that key amino acid substitutions  
67 (methionine to leucine at position 1058 and serine to alanine at position 1060) in the spike  
68 protein of FCoV may be associated with FCoV virulence<sup>14</sup> or systemic infection<sup>11</sup>, therefore  
69 these substitutions were evaluated in FCoV positive effusions.

70 **Methods**

71 Fifty-nine samples of surplus abdominal, pleural and pericardial effusion, from 45 cats,  
72 submitted to the Diagnostic Laboratories of Langford Veterinary Services 2011-2012, were  
73 used. Samples had been collected into tubes containing either RNAlater (Sigma-Aldrich, UK),  
74 EDTA, or no preservative and stored at -20°C upon receipt. All cases classified as FIP were  
75 diagnosed by histopathology and subsequent immunohistological demonstration of FCoV  
76 antigen within macrophages in the lesions, whilst all cases classified as non-FIP were confirmed  
77 to have other diseases based on either histopathology and/or the presence of definitive  
78 diagnostic features of another disease (Table 1). Cases that could not be definitively classified  
79 were excluded from further analysis.

80 Total RNA was purified from 100µl of each effusion sample using a NucleoSpin® RNA II kit  
81 (Macherey-Nagel, Fisher, UK), eluted in 50µl RNase-free water and stored at -80°C.

82 Quantitative RT-PCR was carried out as described previously<sup>11</sup>. A previous study has evaluated  
83 this qRT-PCR assay, and reported a reaction efficiency of 95.9%<sup>15</sup>. The assay has a sensitivity  
84 of between 1 and 10 copies of FCoV per assay (data not shown). Positive and negative controls  
85 (FCoV cDNA and RNase-free water, respectively) were used in all PCR runs. In cats where  
86 more than one type of effusion was collected and/or into different preservatives, only the sample  
87 yielding the lowest threshold cycle (C<sub>T</sub>) value was used in analysis.

88 Pyrosequencing was performed on the FCoV qRT-PCR positive samples to identify methionine  
89 to leucine substitutions at position 1058 (M1058L) in the spike protein. A second substitution at  
90 position 1060 (serine to alanine; S1060A), was investigated using Sanger sequencing on  
91 samples showing methionine at position 1058. Methods were as described previously<sup>11</sup>.

92 Positive and negative controls (control oligonucleotide or FCoV cDNA and RNase-free water,  
93 respectively) were used in all pyrosequencing and PCR sequencing runs.

94 Sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) of effusion qRT-  
95 PCR for the diagnosis of FIP were calculated (MedCalc Software bvba, Belgium).

## 96 **Results**

97 Of the 45 cats, 20 (44%) were classified as FIP, 23 (51%) as non-FIP and two (5%) were  
98 unclassified and thus excluded (Table 1). Of the 20 FIP cats, one effusion sample was obtained  
99 from 13 cats, two samples from six cats and three samples from one cat. Of the 23 non-FIP  
100 cats, one sample was obtained from 19 cats, two samples from three cats and three samples  
101 from one cat. Samples varied by collection site and/or preservative (Table 1). All collected  
102 samples were analysed by qRT-PCR, but as only one sample from each cat was used for  
103 analysis, a total of 43 samples were used.

104 Seventeen of 20 cats (85%) with FIP had FCoV positive effusions, with  $C_T$  values of 24.06-  
105 38.27 (median 31.05). None of the 23 non-FIP cats had FCoV positive effusions (Table 1). All  
106 negative and positive controls gave appropriate results. The effusion FCoV qRT-PCR assay  
107 had a sensitivity of 85%, a specificity of 100%, a PPV of 100% and a NPV of 88.5% for the  
108 diagnosis of FIP (Table 2). The 95% confidence intervals are also shown in Table 2.

109 Pyrosequencing showed that of the 17 FCoV positive effusion FIP cats, 11 (65%) had leucine,  
110 and two (12%) had methionine, at position 1058. Reliable sequence data could not be obtained  
111 for four (23%) cats (Table 1). Of the two cats with methionine at position 1058, only one had  
112 alanine at position 1060. Controls for all assays were appropriately positive and negative.

## 113 **Discussion**

114 We have investigated the presence of FCoV RNA in abdominal, pleural or pericardial effusion  
115 samples from cats with and without FIP. Our results show that in this group of samples, a  
116 positive FCoV qRT-PCR result was highly specific, with no non-FIP cats generating positive  
117 results. However, sensitivity was only 85%. These figures are similar to those recently reported

118 for cerebrospinal fluid FCoV qRT-PCR in cats with neurological and/or ocular FIP and non-FIP  
119 cats, where a specificity of 100% and sensitivity of 85.7% for FIP were reported<sup>16</sup>.

120 The C<sub>T</sub> values of positive qRT-PCR results were 24.1-38.3, representing a ~16,000 fold  
121 variation in the level of FCoV RNA present. Indeed, the C<sub>T</sub> values of 7/17 FCoV positive cats  
122 were >34.0, representing relatively low levels of FCoV RNA. It is possible that the samples from  
123 the three FIP cases that generated negative FCoV qRT-PCR results had FCoV present, but at  
124 levels below the limit of detection of the PCR. Repeated analysis of samples containing levels  
125 of RNA close to the detection limit of the PCR assay can generate either positive or negative  
126 results, dependent on whether adequate template is present in the aliquot used in the PCR<sup>15</sup>.

127 Additionally, levels of FCoV in cats with FIP vary in different tissues, likely mirroring the  
128 pathological changes present<sup>5</sup>, and in some cases are too low to be detected by PCR<sup>5, 11, 17</sup>,  
129 lending support to the premise that negative results in FIP cases may be due to the presence of  
130 very low levels of FCoV in these effusions. A recent study by Pedersen et al<sup>5</sup> reported that the  
131 cellular portion of ascitic FIP samples had 10-1000 times more viral RNA than the supernatant,  
132 with most FCoV within macrophages of the effusion. Thus, in the future, it would be interesting  
133 to perform FCoV qRT-PCR on effusion samples subjected to centrifugation, in an attempt to  
134 concentrate cellular material and any FCoV present, and potentially improve sensitivity.

135 The finding that FCoV was not detectable in any of the non-FIP cats contributed to the high  
136 specificity seen for the PCR. Feline coronavirus infection can be systemic in non-FIP cats<sup>10, 11</sup>,  
137 <sup>18-20</sup>, therefore some FCoV positive effusion samples might have been expected in our non-FIP  
138 group. Lack of such cases may be due to the nature of those included in the study. A large  
139 number of non-FIP cats had neoplasia and these cats tended to be older than the FIP cats, so  
140 may have been less likely to be infected with FCoV. The true FCoV status of the non-FIP cases  
141 could not be determined for this study. Furthermore, FCoV levels in systemic FCoV-infected



142 non-FIP cats are often low<sup>10, 11</sup>, and may have been below the sensitivity of the FCoV qRT-PCR  
143 assay. A possible limitation of this study is the general recruitment of effusion samples  
144 submitted to a diagnostic laboratory, rather than targeting samples in which FIP was suspected  
145 as a major differential diagnosis. Non-targeted recruitment was performed to maximise case  
146 numbers, however, some cats in the non-FIP group presented with inflammatory disease,  
147 where FIP would have been considered a differential.

148 Our study found that the majority of effusions from FIP cats that generated FCoV sequence  
149 data for the amino acid positions 1058 and 1060 contained substitutions concordant with the  
150 systemic form of FCoV<sup>11</sup> and virulence<sup>14</sup>. Only one FIP cat generated sequence data previously  
151 associated with non-systemic (enteric) FCoV<sup>11</sup> or in healthy <sup>14</sup> cats, with methionine and serine  
152 at positions 1058 and 1060 respectively. The FCoV in this cat may have had alternative  
153 substitutions elsewhere in the genome responsible for systemic FCoV virulence.

154 In conclusion, this study suggests that a positive FCoV qRT-PCR result on effusions is highly  
155 indicative of FIP, and may therefore be a useful diagnostic tool in the investigation of suspected  
156 cases that present with an effusion. However, further evaluation of this test's sensitivity and  
157 specificity is required, using a larger sample size that includes FCoV-infected cats that do not  
158 have FIP.

159

## 160 **Acknowledgements**

161 VC and LL held posts Feline Fellowship posts at the University of Bristol funded by Zoetis. SH's  
162 vacation research award was supported by The Wellcome Trust. EP's PhD studentship was  
163 generously funded by The Petplan Charitable Trust. The authors would also like to thank  
164 Michael Day, for his help with histopathology, Anja Kipar for detection of intracellular FCoV  
165 antigen by immunostaining, and both Stuart Siddell and Tim Gruffydd-Jones for intellectual

166 guidance during the study. Additionally thanks are given to the numerous veterinary surgeons  
167 and breeders that submit valuable samples to us for use in our FCoV research.

168

#### 169 **Conflict of Interest**

170 The authors do not have any potential conflicts of interest to declare.

171

#### 172 **Funding**

173 VC and LL held posts Feline Fellowship posts at the University of Bristol funded by Zoetis. SH's  
174 vacation research award was supported by The Wellcome Trust. EP's PhD studentship was  
175 generously funded by The Petplan Charitable Trust.

176

#### 177 **References**

- 178 1.Kipar A and Meli ML. **Feline Infectious Peritonitis: Still an Enigma?** *Vet Path.* 2014; 51:  
179 505-26.
- 180 2.Pedersen NC. **An update on feline infectious peritonitis: diagnostics and therapeutics.**  
181 *Vet J.* 2014; 201: 133-41.
- 182 3.Pedersen NC. **An update on feline infectious peritonitis: virology and**  
183 **immunopathogenesis.** *Vet J.* 2014; 201: 123-32.
- 184 4.Bauer BS, Kerr ME, Sandmeyer LS and Grahn BH. **Positive immunostaining for feline**  
185 **infectious peritonitis (FIP) in a Sphinx cat with cutaneous lesions and bilateral**  
186 **panuveitis.** *Vet Ophthalmol.* 2013; 16 Suppl 1: 160-3.
- 187 5.Pedersen NC, Eckstrand C, Liu H, Leutenegger C and Murphy B. **Levels of feline infectious**  
188 **peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in**  
189 **disease outcome following experimental infection.** *Vet Microbiol.* 2015; 175: 157-66.

190 6.Litster AL, Pogradichniy R and Lin TL. **Diagnostic utility of a direct immunofluorescence**  
191 **test to detect feline coronavirus antigen in macrophages in effusive feline infectious**  
192 **peritonitis.** *Vet J.* 2013; 198: 362-6.

193 7.Paltrinieri S, Cammarata MP and Cammarata G. **In vivo diagnosis of feline infectious**  
194 **peritonitis by comparison of protein content, cytology, and direct immunofluorescence**  
195 **test on peritoneal and pleural effusions.** *J Vet Diag Invest.* 1999; 11: 358-61.

196 8.Parodi MC, Cammarata G, Paltrinieri S, Lavazza A and Ape F. **Using Direct**  
197 **Immunofluorescence to Detect Coronaviruses in Peritoneal and Pleural Effusions.** *J Small*  
198 *Anim Pract.* 1993; 34: 609-13.

199 9.Hartmann K, Binder C, Hirschberger J, et al. **Comparison of different tests to diagnose**  
200 **feline infectious peritonitis.** *J Vet Int Med.* 2003; 17: 781-90.

201 10.Kipar A, Baptiste K, Barth A and Reinacher M. **Natural FCoV infection: cats with FIP**  
202 **exhibit significantly higher viral loads than healthy infected cats.** *J Feline Med Surg.* 2006;  
203 8: 69-72.

204 11.Porter E, Tasker S, Day MJ, et al. **Amino acid changes in the spike protein of feline**  
205 **coronavirus correlate with systemic spread of virus from the intestine and not with feline**  
206 **infectious peritonitis.** *Vet Res.* 2014; 45: 49.

207 12.Soma T, Wada M, Taharaguchi S and Tajima T. **Detection of ascitic feline coronavirus**  
208 **RNA from cats with clinically suspected feline infectious peritonitis.** *J Vet Med Sci.* 2013;  
209 75: 1389-92.

210 13.Tsai HY, Chueh LL, Lin CN and Su BL. **Clinicopathological findings and disease staging**  
211 **of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan.** *J Feline Med Surg.*  
212 2011; 13: 74-80.

- 213 14.Chang HW, Egberink HF, Halpin R, Spiro DJ and Rottier PJ. **Spike protein fusion Peptide**  
214 **and feline coronavirus virulence.** *Emerg Infect Dis.* 2012; 18: 1089-95.
- 215 15.Dye C, Helps CR and Siddell SG. **Evaluation of real-time RT-PCR for the quantification**  
216 **of FCoV shedding in the faeces of domestic cats.** *J Feline Med Surg.* 2008; 10: 167-74.
- 217 16.Doenges SJ, Weber K, Dorsch R, et al. **Detection of feline coronavirus in cerebrospinal**  
218 **fluid for diagnosis of feline infectious peritonitis in cats with and without neurological**  
219 **signs.** *J Feline Med Surg.* 2015; In press Mar 3. DOI: 10.1177/1098612X15574757.
- 220 17.Paltrinieri S. **Human severe acute respiratory syndrome (SARS) and feline**  
221 **coronaviroses.** *J Feline Med Surg.* 2004; 6: 131-2.
- 222 18.Can-Sahna K, Soydal Ataseven V, Pinar D and Oguzoglu TC. **The detection of feline**  
223 **coronaviruses in blood samples from cats by mRNA RT-PCR.** *J Feline Med Surg.* 2007; 9:  
224 369-72.
- 225 19.Gunn-Moore DA, Gruffydd-Jones TJ and Harbour DA. **Detection of feline coronaviruses**  
226 **by culture and reverse transcriptase-polymerase chain reaction of blood samples from**  
227 **healthy cats and cats with clinical feline infectious peritonitis.** *Vet Microbiol.* 1998; 62: 193-  
228 205.
- 229 20.Kipar A, Meli ML, Baptiste KE, Bowker LJ and Lutz H. **Sites of feline coronavirus**  
230 **persistence in healthy cats.** *J Gen Virol.* 2010; 91: 1698-707.



232 **Table 1. Characteristics of effusion samples from the 45 cats recruited in the study.**

Cat number	FIP classification	Age (years)	Sex	Breed	Diagnosis	Source of effusion sample	Preservative	C <sub>T</sub> value for FCoV qRT-PCR	Pyrosequencing result for position 1058
1	FIP	-	-	-	FIP	Abdominal	None	24.06	Leucine
2	FIP	0.6	M	DSH	FIP	Pleural	EDTA	24.38	Leucine
3	FIP	0.6	MN	Ragdoll	FIP	Abdominal	None	26.64	Leucine
4	FIP	0.4	-	DSH	FIP	Pleural	RNAlater	27.05	Leucine
5	FIP	-	-	DSH	FIP	Pleural	None	27.98	Methionine <sup>1</sup>
6	FIP	0.4	ME	Scottish Fold	FIP	Pleural	None	29.47	Leucine
7	FIP	-	M	DSH	FIP	Abdominal	None	30.10	Leucine
8	FIP	3	FN	-	FIP	Abdominal	None	30.66	Leucine
9	FIP	0.7	FE	Ragdoll	FIP	Abdominal	None	31.05	Methionine <sup>2</sup>
10	FIP	0.3	ME	Bengal cross	FIP	Abdominal	EDTA	33.94	No clear sequence

11	FIP	0.4	M	BSH	FIP	Pleural	None	35.02	No clear sequence
12	FIP	3	MN	DSH	FIP	Pericardial	EDTA	35.72	Leucine
13	FIP	1	F	BSH	FIP	Abdominal	EDTA	36.17	Leucine
14	FIP	0.7	-	Korat	FIP	Abdominal	RNA later	36.96	Leucine
15	FIP	0.4	FE	Savannah	FIP	Abdominal	None	37.01	No clear sequence
16	FIP	0.3	M	Bengal	FIP	Abdominal	EDTA	37.81	Leucine
17	FIP	0.4	FE	DSH	FIP	Abdominal	RNA later	38.27	No clear sequence
18	FIP	7	FN	DSH	FIP	Abdominal	None	No C <sub>T</sub>	ND
19	FIP	0.9	MN	Bengal	FIP	Abdominal	None	No C <sub>T</sub>	ND
20	FIP	7	FN	Birman	FIP	Abdominal	None	No C <sub>T</sub>	ND
21	Non-FIP	13	FN	DSH	Thymoma with associated chylothorax	Pleural	None	No C <sub>T</sub>	ND

22	Non-FIP	9	MN	DSH	Lymphohistiocytic thoracic neoplasm	Pleural	EDTA	No C <sub>T</sub>	ND
23	Non-FIP	13	MN	DSH	Hyperthyroidism and hypertrophic cardiomyopathy associated congestive cardiac failure	Pleural	EDTA	No C <sub>T</sub>	ND
24	Non-FIP	18	FN	DSH	Severe protein losing enteropathy	Abdominal	None	No C <sub>T</sub>	ND
25	Non-FIP	0.3	M	Exotic	Idiopathic chylothorax	Pleural	EDTA	No C <sub>T</sub>	ND
26	Non-FIP	8	FN	DSH	Intestinal carcinomatosis	Abdominal	EDTA	No C <sub>T</sub>	ND
27	Non-FIP	10	FN	DSH	Cholangiocarcinoma with carcinomatosis	Abdominal	None	No C <sub>T</sub>	ND
28	Non-FIP	1	FN	Maine Coon	Fibrous (non-inflammatory) lesions present throughout abdominal cavity – aetiology not known	Pleural	None	No C <sub>T</sub>	ND
29	Non-FIP	10	FN	Somali	Feline triaditis (pancreatitis,	Abdominal	None	No C <sub>T</sub>	ND



					cholangitis and inflammatory bowel disease)				
30	Non-FIP	15	MN	DSH	Large cell lymphoma of small intestine and liver	Abdominal	None	No C <sub>T</sub>	ND
31	Non-FIP	8	FN	DSH	Thymoma	Pleural	EDTA	No C <sub>T</sub>	ND
32	Non-FIP	11	FN	DSH	Possible mesothelioma, with mild neutrophilic inflammation	Pleural	EDTA	No C <sub>T</sub>	ND
33	Non-FIP	4	FN	Persian	Intestinal lymphoma	Abdominal	EDTA	No C <sub>T</sub>	ND
34	Non-FIP	10	FN	DLH	Abdominal carcinoma	Abdominal	EDTA	No C <sub>T</sub>	ND
35	Non-FIP	1	FE	Russian Blue	Haemorrhagic effusion	Abdominal	None	No C <sub>T</sub>	ND
36	Non-FIP	8	FN	DSH	Hepatic carcinoma	Abdominal	None	No C <sub>T</sub>	ND
37	Non-FIP	8	MN	DSH	Chemodectoma	Pleural	None	No C <sub>T</sub>	ND
38	Non-FIP	2	MN	Tonkinese	Abdominal carcinoma	Abdominal	EDTA	No C <sub>T</sub>	ND
39	Non-FIP	13	MN	Birman	Restrictive cardiomyopathy	Pleural	EDTA	No C <sub>T</sub>	ND

40	Non-FIP	3	F	BSH	Neutrophilic cholangitis	Abdomi nal	RNA later	No C <sub>T</sub>	ND
41	Non-FIP	7	MN	Devon Rex	Lymphoplasmacytic inflammation of the liver and kidney	Abdomi nal	None	No C <sub>T</sub>	ND
42	Non-FIP	8	MN	DLH	Uroabdomen	Pleural	EDTA	No C <sub>T</sub>	ND
43	Non-FIP	11	MN	Maine Coon	Diaphragmatic rupture	Pleural	None	No C <sub>T</sub>	ND
44	Unclassified	1	FN	Maine Coon	Pyothorax but could not rule out FIP as an underlying cause	Abdomi nal	EDTA	No C <sub>T</sub>	ND
45	Unclassified	12	MN	Russian Blue	Unable to determine definitive diagnosis	Abdomi nal	EDTA	No C <sub>T</sub>	ND

233

234 - = Unknown, C<sub>T</sub> = Threshold cycle value, qRT-PCR = reverse transcriptase quantitative polymerase chain reaction, FCoV =

235 feline coronavirus

236 DSH = Domestic Shorthair, BSH = British Shorthair, DLH = Domestic Longhair, M = male, F = female, N = neutered, E =

237 entire

238 ND = Samples negative for FCoV RNA by qRT-PCR which were therefore not submitted for pyrosequencing

239 <sup>1</sup> Sequencing result for position 1060 = Alanine

240 <sup>2</sup> Sequencing result for position 1060 = Serine.

241

242  
243 **Table 2. Sensitivity, specificity, and positive and negative predictive values of effusion**  
244 **reverse transcriptase quantitative polymerase chain reaction for the diagnosis of FIP**  
245

	<b>Value</b>	<b>95% Confidence intervals</b>
<b>Sensitivity</b>	85.0%	65.1 - 96.8%
<b>Specificity</b>	100.0%	85.2 – 100.0%
<b>Positive predictive value</b>	100.0%	80.5 – 100.0%
<b>Negative predictive value</b>	88.5%	69.9 - 97.6%
<b>Prevalence of FIP</b>	46.5%	31.5 – 62.2%

246  
247  
248  
249  
250  
251

252

253